

Att. Docket No.: REG 780D

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Murphy et al.

Serial No.: 10/076,840

Group: Not Yet Assigned


Filing Date: February 15, 2002

Examiner: Not Yet Assigned

Title: METHODS OF MODIFYING EUKARYOTIC CELLS

FIRST CLASS MAIL CERTIFICATE

I hereby certify that this document is being deposited with the United States Postal Service on this date as first class mail addressed to: MS Information Disclosure Statement, Commissioner for Patents, United States Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450.


Loren Hernandez

April 16, 2004
Date

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.56 and 1.97**

Commissioner for Patents
US Patent & Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In compliance with the applicant's duty to submit information material to patentability of the above-referenced case, Applicants herein submit the following Information Disclosure Statement with the accompanying PTO Form 1449 and copies of references listed therein. The PTO is kindly requested to make of record those references, which may be pertinent to the examination of the above-referenced application.

This Information Disclosure Statement is being filed:


Within three months of the filing date of the above referenced application; within three months of the entry of an international application into the national phase; before the mailing date of a first Office action on the merits; or before the mailing of a first Office action after the filing of a request for continued examination under § 1.114. Accordingly, no fee is required for the submission.

Each item of information contained in these IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the date of the filing of these IDS.

FEES

No fee deemed necessary. If any additional fee should be deemed necessary, the Commissioner is hereby authorized to charge Deposit Account Number 18-0650.

Respectfully submitted



Valeta Gregg

Reg. No. 35,127

Regeneron Pharmaceuticals, Inc.

777 Old Saw Mill River Road

Tarrytown, New York 10591

(914) 345-7400



FORM PTO-1449

Att. Docket No. REG 780D

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Att. Docket No. : REG 780D
Serial No. : 10/076,840
Applicant: : Murphy et al.
Date Filed : February 15, 2002
For : METHODS OF MODIFYING
EUKARYOTIC CELLS
Examiner : Not Yet Known
Group Art Unit : Not Yet Known

Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

U.S. PATENT DOCUMENTS

<u>Examiner Initials</u>	<u>Patent Number</u>	<u>Patent Date</u>	<u>Name</u>	<u>Class/ Subclass</u>	<u>Filing Date</u>
_____	_____	_____	_____	_____	_____

FOREIGN PATENT DOCUMENTS

<u>Examiner Initials</u>	<u>Document Number</u>	<u>Date</u>	<u>Country</u>	<u>Class/ Subclass</u>	<u>Translation Yes No</u>
_____	_____	_____	_____	_____	_____

REG 780D
USSN : 10/076,840
PTO 1449 Form
Murphy et al.
Page 2



OTHER DOCUMENTS

Examiner
Initials

_____ Jessen, et al., Proc. Natl. Acad. Sci. USA, Vol. 95, pp. 5121-5126, (1998).

EXAMINER
CONSIDERED

DATE

EXAMINER:

Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Respectfully submitted,

By:

Valetta Gregg
Valeta Gregg
Reg. No. 35,127
Attorneys for Applicant
Patent Agent for Applicant
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
(914) 345-7400